FHD-609

Overview

FHD-609 is a BRD9 PROTAC degrader. FHD-609 induces BRD9 degradation, downregulates primary transcripts of HBG/HBD , Myc expression and proliferation gene sets, reduces the levels of synovial sarcoma tumor proliferation markers, and inhibits tumor growth. FHD-609 can be used in research related to advanced synovial sarcoma, SMARCB1-deficient tumors and adrenocortical carcinoma. (Pink: BRD9 ligand ( HY-49393 ); Blue: Cereblon ligand ( HY-168308 ); Black: linker ( HY-168309 )).

Application

Products | Products > Disease Areas > Cancer | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Disease Areas > Leukemia/Lymphoma/Myeloma | Products > Disease Areas > Blood Disease | Products > Disease Areas > Hypothalamic-Pituitary-Adrenal Regulation | Products > Disease Areas > Osteosarcoma | Products > Disease Areas > Acute Myeloid Leukemia | Products > Disease Areas > Adrenal Cancer | Products > Signaling Pathways > PROTAC | Products > Signaling Pathways > Epigenetics | Products > Signaling Pathways > Apoptosis | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Research Areas > Endocrinology | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > PROTACs | Products > Signaling Pathways > Epigenetic Reader Domain | Products > Signaling Pathways > c-Myc | Products > Signaling Pathways > Hemoglobin

Product Information

• Catalog No.: HY-153367
• CAS No.: 2676211-64-4
• Molecular Formula: C47H56N8O6
• Molecular Weight: 829.00
• Purity: 98.95%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: ≥ 2.5 mg/mL (3.02 mM); Clear solution
• Availability: In-stock

Source

Original product source